Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Metabolic & GLP-1 research

Adipotide (Prohibitin-TP01): Research Overview

Experimental fat-targeting compound whose development stopped after kidney safety signals.

Also known as Prohibitin-TP01 · adipotide FTPP

Research use onlyStrongest evidence: animal studyReviewed
DatabaseReferences

What is Adipotide?

Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.

What is Adipotide researched for?

  • CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
  • Selective white adipose tissue vascular targeting produced 7-15% body-weight loss over 4 weeks in obese macaques.
  • Improved insulin response (reduced insulin AUC) following fat-mass reduction in primates.
  • Weight loss without primary appetite suppression; peripheral vascular approach.

How does Adipotide work?

Adipotide targets adipose tissue vascular endothelium directly, causing localized endothelial apoptosis and adipocyte loss via a peripheral vascular mechanism. Semaglutide suppresses appetite centrally via GLP-1 receptors. Adipotide achieves weight loss without appetite suppression, making it mechanistically distinct from appetite suppressants.

Reported targets: GLP-1 receptor

References

  1. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

    2011

    Rhesus macaques at 0.43 mg/kg SC daily for 28 days showed 7.4-14.7% weight loss; insulin resistance improved; mild, dose-dependent, reversible proximal tubule changes.

    Animal study

  2. Reversal of obesity by targeted ablation of adipose tissue

    2004

    Mice with diet-induced obesity showed ~30% weight reduction; adipose vascular apoptosis; metabolic normalization.

    Animal study

  3. Prohibitin/Annexin A2 Interaction Regulates Fatty-Acid Transport

    2016

    Mechanistic validation of prohibitin/ANXA2 axis in adipose tissue, core to TP01 targeting.

  4. Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability

    2025

    Next-generation prohibitin constructs improve serum stability and efficacy vs. first-generation TP01.